Optimization of postremission therapy in follicular lymphoma: Efficacy of rituximab maintenance

Rupali Roy; Leo I. Gordon

doi:10.6004/jnccn.2011.0047

Optimization of postremission therapy in follicular lymphoma: Efficacy of rituximab maintenance

Rupali Roy^*, Leo I. Gordon

^*Corresponding author for this work

Medicine, Hematology Oncology Division

Research output: Contribution to journal › Article › peer-review

Abstract

Rituximab has been proven to be an important part of the treatment of newly diagnosed and relapsed or refractory follicular lymphoma both alone and in combination with chemotherapy. Given its tolerability, rituximab has now been investigated in the maintenance setting in an effort to further improve progression-free and overall survival in patients with follicular lymphoma.

Original language	English (US)
Pages (from-to)	563-571
Number of pages	9
Journal	JNCCN Journal of the National Comprehensive Cancer Network
Volume	9
Issue number	5
DOIs	https://doi.org/10.6004/jnccn.2011.0047
State	Published - May 1 2011

Keywords

Follicular lymphoma
Non-Hodgkin's lymphoma
Rituximab
Rituximab maintenance

ASJC Scopus subject areas

Oncology

Access to Document

10.6004/jnccn.2011.0047

Cite this

@article{5a4553db6a584b139d056de0027642e8,

title = "Optimization of postremission therapy in follicular lymphoma: Efficacy of rituximab maintenance",

abstract = "Rituximab has been proven to be an important part of the treatment of newly diagnosed and relapsed or refractory follicular lymphoma both alone and in combination with chemotherapy. Given its tolerability, rituximab has now been investigated in the maintenance setting in an effort to further improve progression-free and overall survival in patients with follicular lymphoma.",

keywords = "Follicular lymphoma, Non-Hodgkin's lymphoma, Rituximab, Rituximab maintenance",

author = "Rupali Roy and Gordon, {Leo I.}",

year = "2011",

month = may,

day = "1",

doi = "10.6004/jnccn.2011.0047",

language = "English (US)",

volume = "9",

pages = "563--571",

journal = "JNCCN Journal of the National Comprehensive Cancer Network",

issn = "1540-1405",

publisher = "Cold Spring Publishing LLC",

number = "5",

}

TY - JOUR

T1 - Optimization of postremission therapy in follicular lymphoma

T2 - Efficacy of rituximab maintenance

AU - Roy, Rupali

AU - Gordon, Leo I.

PY - 2011/5/1

Y1 - 2011/5/1

N2 - Rituximab has been proven to be an important part of the treatment of newly diagnosed and relapsed or refractory follicular lymphoma both alone and in combination with chemotherapy. Given its tolerability, rituximab has now been investigated in the maintenance setting in an effort to further improve progression-free and overall survival in patients with follicular lymphoma.

AB - Rituximab has been proven to be an important part of the treatment of newly diagnosed and relapsed or refractory follicular lymphoma both alone and in combination with chemotherapy. Given its tolerability, rituximab has now been investigated in the maintenance setting in an effort to further improve progression-free and overall survival in patients with follicular lymphoma.

KW - Follicular lymphoma

KW - Non-Hodgkin's lymphoma

KW - Rituximab

KW - Rituximab maintenance

UR - http://www.scopus.com/inward/record.url?scp=79955834642&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79955834642&partnerID=8YFLogxK

U2 - 10.6004/jnccn.2011.0047

DO - 10.6004/jnccn.2011.0047

M3 - Article

C2 - 21550969

AN - SCOPUS:79955834642

SN - 1540-1405

VL - 9

SP - 563

EP - 571

JO - JNCCN Journal of the National Comprehensive Cancer Network

JF - JNCCN Journal of the National Comprehensive Cancer Network

IS - 5

ER -

Optimization of postremission therapy in follicular lymphoma: Efficacy of rituximab maintenance

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this